|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
CLINVAR |
|
|
|
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In this series of ovarian tumours, LOH on 17p correlates closely with the aberrant expression of the p53 protein in a high proportion of advanced stage serous adenocarcinomas.
|
1310251 |
1992 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Our study indicates that there might be an association between accumulation of p53 protein and c-myc over-expression in non-small-cell lung cancer, and that this in particular might apply to adenocarcinomas.
|
1334053 |
1992 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Among four adenocarcinomas arising in the lowest portion of the uterine corpus, three showed integration of human papillomavirus (HPV) types 16 and/or 18 DNA, and two of them also showed p53 mutation.
|
1336492 |
1992 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining for the p53 protein was performed in 107 snap frozen primary endometrial adenocarcinomas and 15 benign uterine tissues using monoclonal antibody PAb1801.
|
1540970 |
1992 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
These genes include 1) those important to androgen metabolism in the prostate, the androgen receptor and steroid 5 alpha reductase genes; 2) those that map to the 10q (PLAU) and 7q (MET) chromosomal regions found deleted in some prostate carcinomas, and 3) proto-oncogenes (ERBB2, INT2, and MYC) and tumor suppressor gene loci (RB1, TP53 and D17S5) found altered in adenocarcinomas of the breast, colon and lung.
|
1552612 |
1992 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Although the number of p53 negative adenocarcinomas without metastasis was larger than the number of p53 positive tumors without metastasis, there were not clear differences between p53 positive and negative tumors with metastasis.
|
1656762 |
1991 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We analyzed 15 aneuploid populations and one tetraploid populations from 13 Barrett's adenocarcinomas for 17p allelic deletions and p53 protein overexpression to determine whether both of these alterations are involved in carcinogenesis in Barrett's esophagus.
|
1680552 |
1991 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Mucinous carcinomas and right-side carcinomas were less p53 immunoreactive (25% and 52%, respectively) than the usual adenocarcinomas (73%) and distal tumors (72%).
|
1868464 |
1991 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
However, the finding of p53 mutations in Barrett's epithelium adjacent to adenocarcinomas may have clinical implications for p53 as a premalignant marker for esophageal cancer.
|
1943188 |
1991 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Simultaneous monitoring of P53 protein and DNA content of colorectal adenocarcinomas by flow cytometry.
|
2137812 |
1990 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We have found that the expression of p53 messenger RNA is growth regulated in human cells following kinetics similar to that previously shown in mouse 3T3 cells, and is increased in the large majority of colon adenocarcinomas in comparison to adjacent normal mucosa and adenoma.
|
3019534 |
1986 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
The statistical significance was maintained even when the comparison was restricted to strong p53 staining in moderately to poorly differentiated adenocarcinomas (P < 0.05).
|
7520348 |
1994 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
No significant correlation was observed between p53 protein expression and most of the clinico-pathological and flow-cytometric parameters (sex, age, tobacco smoking, chronic alcohol consumption, size of the tumor, grade of differentiation, depth of infiltration, presence of lymph node metastases, UICC stage, DNA-ploidy, S phase fraction). p53 protein expression was more frequent in Lauren's intestinal adenocarcinomas (67%) when compared to the diffuse type tumors (24%) (p = 0.002).
|
7540752 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Although structural mutations in the p53 gene have been implicated in late-stage prostate cancer, little is known about the p53 response to genotoxic stress in normal human prostatic epithelial cells from which adenocarcinomas originate.
|
7543816 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This indicated that p53 point mutations may play a less crucial part in malignant conversion of adenoma to adenocarcinoma in the stomach than in the colon.
|
7582240 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We studied 51 cervical carcinomas, among them 25 squamous-cell carcinomas (SCC) and 26 cervical adenocarcinomas (AdCa), and 40 vulvar SCC for the presence of HPV and mutant p53.
|
7591279 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
However, metastatic prostatic tumors are found to display a higher percentage (21.4%) of p53 mutations compared with primary adenocarcinomas (9.8%).
|
7604888 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study examined the association between 17p allelic loss and p53 gene mutation in a series of 16 esophageal adenocarcinomas arising on a background of Barrett's esophagus.
|
7614480 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Frequencies of p53 mutations and serum antibodies were higher in squamous cell carcinoma patients than in adenocarcinoma.
|
7622306 |
1995 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Thus, these data indicate that the mutational status of p53 is predictive of chemosensitivity of gastric and esophageal adenocarcinomas, and suggest a mechanism in which p53 protein contributes to the cellular response to chemotherapy.
|
7665247 |
1995 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The immunohistochemical finding of p53 protein in primary esophageal adenocarcinomas and regional lymph node metastases appears to be associated with reduced overall survival for this disease.
|
7666667 |
1995 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Protein expression of p53 and Rb suppressor genes during the first passages of human endometrial adenocarcinomas heterotransplanted into nude mice.
|
7669947 |
1995 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Increased p53 immunoreactivity was observed in only 6% (1/16) of prostatic adenocarcinomas with a total Gleason score of 6 or less, as compared with 45% (9/20) of those adenocarcinomas with a Gleason score of 7 or more.
|
7675761 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
As to the prognosis, there were no significant differences between the p53 gene alteration-positive and -negative cases in both the younger and older groups as well as in all subjects, while a tendency of poorer prognosis was observed in K-ras gene alteration-positive cases than for the -negative ones with adenocarcinomas.
|
7715905 |
1995 |